Annovis Bio, Inc.

ANVSSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1477845

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$0.00	$0.00	$0.00	$0.00	$0.00
Research and Development Expense	$20.0M	$38.8M	$16.5M	$8.5M	$3.1M
Operating Expenses	$26.7M	$45.0M	$25.5M	$14.5M	$6.6M
Operating Income (Loss)	-$26.7M	-$45.0M	-$25.5M	-$14.5M	-$6.6M
Nonoperating Income (Expense)	$2.1M	-$11.2M	$182.7K	$50.1K	$1.2M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	—	-$25.3M	-$14.5M	-$5.5M
Income Tax Expense (Benefit)	$0.00	—	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$13.9M	$10.2M	$36.0M	$46.0M	$8.1M
Assets, Current	—	—	$36.0M	$46.0M	$8.1M
Cash and Cash Equivalents, at Carrying Value	$10.6M	$5.8M	$28.4M	$45.7M	$8.1M
Liabilities	$4.6M	$18.0M	$7.7M	$1.5M	$578.4K
Liabilities, Current	$3.9M	$4.3M	$7.7M	$1.5M	$578.4K
Accounts Payable, Current	$2.3M	$1.3M	$4.0M	$688.1K	$341.9K
Stockholders' Equity Attributable to Parent	-$7.8M	$28.3M	$44.5M	$7.5M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$21.9M	-$40.0M	-$17.3M	-$9.1M	-$4.0M
Net Cash Provided by (Used in) Financing Activities	$26.7M	$17.3M	$4.6K	$46.7M	$12.0M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)